HLA Typing for Transplant Market Size By Technology (Non-Molecular Assays [Serological Assays, Mixed Lymphocyte Culture Assays], Molecular Assays [PCR Based Molecular Assays, Sequencing Based Molecular Assays {Sanger Sequencing, Next Generation Sequencing}]), By Product and Services (Instruments, Reagents and Consumables, Software, Services), By Application (Diagnostics, Research), By End-use (Hospitals, Academic and Research Institutes), Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2020 – 2026

Published Date: Sep 2020  |  Report ID: GMI1653  |  Authors: Sumant Ugalmugle, Rupali Swain

Report Format: PDF   |   Pages: 235   |   Base Year: 2019




Summary Table of Contents Industry Coverage Methodology

Industry Trends

HLA Typing for Transplant Market size valued at over USD 590 million in 2019 and is expected to witness more than 9.6% CAGR between 2020 and 2026.
 

Elderly people are more likely to suffer from several diseases due to anatomic and functional changes along with impaired immune system. Hence, rising geriatric population will act as high impact rendering factor for the growth of HLA typing market. As per the Population Reference Bureau report, number of Americans aged above 65 years is estimated to more than double from 46 million in 2016 to reach over 98 million by 2060. This portion of the population requires various transplant procedure including heart, liver, and kidney transplants.
 

HLA Typing for Transplant Market

Get more details on this report - Request Free Sample PDF
 

The health systems are under tremendous strain, as various healthcare organizations are suspending all non-essential care and procedures due to COVID-19 outbreak. All registries including for HLA typing for transplant have been impacted, as they are experiencing or facing significant challenges exporting the products. To overcome these consequences and in response to COVID-19, in April 2020, FDA released updated information for organizations accumulating human cell and tissue products (HCT/Ps) including PBSC and marrow. Additionally, market players focusing on R&D investments will lead to innovations in HLA typing, influencing the market expansion.
 

Technological advancements in molecular assays segment is driving the global HLA typing for transplant market growth. Presently, target specific PCR method is used to screen disease causative pathogen. Companies are focusing on development of novel platforms for HLA typing. Advancements from initial stages of single pathogen detection to nucleic acid amplification methods have been developed to deliver faster and accurate results. Furthermore, shift from PCR to RT-PCR has revolutionized the identification of DNA and RNA. Advances in genetic sequencing, coupled with innovations in metabolomics and proteomic profiling technologies have created new growth opportunities for more personalized medical approaches.
 

HLA Typing for Transplant Market Report Coverage
Report Coverage Details
Base Year: 2019 Market Size in 2019: USD 594.6 Million
Historical Data for: 2015 to 2019 Forecast Period: 2020 to 2026
Forecast Period 2020 to 2026 CAGR: 9.6% 2026 Value Projection: USD 1,128.0 Million
Pages: 235 Tables, Charts & Figures: 368
Geographies covered (16): U.S., Canada, Germany, UK, France, Italy, Russia, China, Japan, India, Australia, Brazil, Mexico, South Africa, Saudi Arabia
Segments covered: Technology, Product and Services, Application, End-use and Region
Companies covered (19): Abbott, Bio-Rad Reference Inc, BioReference Laboratories, CareDx, GenDx, Illumina Inc, Immucor Inc, Inno-Train Diagnostik GmbH, Luminex Corporation, Ominox Inc, Pacific Bioscience of California, Qiagen N.V., F-Hoffmann-La Roche Ltd, Thermo Fischer Scientific, Fujirebio, BAG Diagnostic GmbH, GMSbiotek Inc, Biofortuna Limited, TBG Diagnostics Limited
Growth Drivers:
  • Increasing number of solid organ transplant
  • Technological advancements
  • Increasing geriatric population
Pitfalls & Challenges:
  • Significant gap between number of organ donated and organ required
  • High cost of molecular tests

Get more details on this report - Request Free Sample PDF
 

Increasing utilization of molecular diagnostics in HLA typing has led to an upsurge in its costs, hampering the market growth

Rising demand for molecular diagnostics due to its ability to deliver accurate results in less time has created pressure on industry players to develop new products to satisfy growing consumer demands. Majority of laboratories perform several molecular tests using hematology and chemistry analyzers. A study indicates that gene sequencing test costs around USD 5,000 to USD 10,000 per test which is not affordable to majority of the population.
 

Advantages associated with PCR based molecular assays will boost the market demand

The PCR based molecular assays segment dominated over 74% of the HLA typing for transplant market share in 2019. PCR technique is used for fast recognition of pathogens. Together with conventional PCR methods, the real-time PCR (RT-PCR) has developed as innovative technology and is increasingly being used in research laboratories and clinical diagnostics. RT-PCR is considered as accurate and fast platform for generation of quantitative as well as qualitative results.
 

Advent of technologies in instruments will serve as a growth opportunity

HLA Typing for Transplant By Technology

Get more details on this report - Request Free Sample PDF
 

The instruments segment is estimated to witness growth rate of over 9.7% during the forecast timeframe. Instruments are now being designed with emphasis on function and cost effectiveness. Advent of modern technologies have enabled development of instruments that provides better and accurate results in less time. Thus, technological advancements will render significant positive impact on the segment growth. Moreover, instruments also have greater shelf life that will further drive the demand for HLA typing instruments.
 

Increasing application in disease diagnosis will foster the HLA typing for transplant market revenue

The diagnostics segment size was over USD 462.6 million in 2019 due to increasing application in disease diagnosis and presence of new specific genetic testing methods. Moreover, application of HLA typing in preimplantation genetic diagnosis (PGD) is increasing. The need for HLA matched bone marrow transplantation treatment for couples at risk with thalassaemic children will further fuel the industry growth.
 

Increasing number of organ transplant in hospital settings

Hospital segment accounted for around 29.5% market share in 2019. Rising number of patients visit and growing number of transplant procedures that occur in hospitals will increase the demand for HLA typing in the coming years. Increasing solid organ and bone marrow transplantation will impel the segment growth of HLA typing in hospitals. Furthermore, presence of sophisticated infrastructure and skilled resources in hospital settings will stimulate the segment demand.
 

Adoption of advanced technologies for organ transplantation in North America

HLA Typing for Transplant Market By Region

Get more details on this report - Request Free Sample PDF
 

North America HLA typing for transplant market held largest revenue share of 35.4% in 2019 owing to presence of majority of the companies involved in the region. HLA typing is also largely practiced in research. A major share of market value is attributed to commercial purpose of HLA typing, that is, organ transplant. Furthermore, factors such as large number and sizes of laboratories and highly skilled professionals will boost the market size expansion.
 

Adoption of business strategies will pave growth opportunities for companies operating in the market

Prominent players operating in the market include Abbott, Bio-Rad Laboratories, CareDx, Qiagen N.V., Thermo Fischer Scientific, F. Hoffmann-La Roche Ltd, Illumina Inc, Luminex Corporation and Immucor, Inc. Partnerships & collaborations, geographical expansion, product approval & launch are the most commonly adopted business strategies to sustain market competition.
 

Some of the recent industry developments:

  • In November 2019, Thermo Fischer Scientific launched its Ion Torrent Genexus system, a next generation sequencing platform. The platform featured automated specimen-to-report workflow that deliver results in a single day. This novel product launch was aimed to add value to their product portfolio and expand their customer base.
     
  • In April 2018, CareDx received CE mark approval for its Olerup QTYPE, a real time HLA typing diagnostic. The Olerup QTYPE provides tissue typing for real time HLA typing of donors and recipients. This approval enabled the firm to extent its geographic outreach as well as customer base.
     

The HLA typing for transplant market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2015 to 2026, for the following segments:
 

Market, By Technology

  • Non-molecular assays
    • Serological assays
    • Mixed lymphocyte culture assays
  • Molecular assays
    • PCR based molecular assays
    • Sequencing based molecular assays
      • Sanger sequencing
      • Next generation sequencing

Market, By Product and Services

  • Instruments
  • Reagents and consumables
  • Software
  • Services

Market, By Application

  • Diagnostics
  • Research

Market, By End-use

  • Hospitals
  • Diagnostic labs
  • Academic and research institutes

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
  • Latin America
    • Brazil
    • Mexico
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
       

Frequently Asked Questions (FAQ) :

Global market size was worth USD 590 million in 2019 and may exhibit 9.6% CAGR through 2026, due to rising geriatric population.
The PCR based molecular assays segment dominated the business in 2019 with a market share of over 74%, as PCR technique is commonly deployed for fast recognition of pathogens.
The instruments segment may witness 9.7% CAGR through 2026, driven by modern technologies that have helped to develop instruments providing highly accurate results in less time.
The diagnostics segment was USD 462.6 million in 2019 and will depict considerable expansion, owing to rising usage in disease diagnosis and advent of new genetic testing methods.
Hospital segment held 29.5% market share in 2019 and will exhibit substantial growth as hospitals host an increasing number of transplant procedures.
In 2019, North America accounted for the largest industry share of 35.4%, driven by the presence of numerous firms in the region and large number of research programs undertaken.

Buy NowImmediate delivery available

Need a Discount? Get in touch with us for special pricing

Request Discount

Connect with our sales team

Premium Report Details

  • Published Date: Sep 2020
  • Pages: 235
  • Tables: 353
  • Charts / Figures: 15
  • Companies covered: 19
  • Countries covered: 16

Benefits of Association

Data Coverage & Quality

GMI reports provide the most comprehensive coverage of any focus industry, ensuring a holistic and deep understanding of the market, along with actionable and granular data. We also take pride in our commitment to quality and strive to ensure that our clients get their moneys worth.

Client Trust & Security

GMI maintains strict code of conduct as a business and is committed to ensure that the privacy and trust of our clients are always maintained. As an organization, we also strive to be fully compliant with privacy laws, PCI and information security guidelines.

Customer Service

Our customers rely on us to produce accurate, reliable and timely information. Service orientation is a key mission for us as an organization; our process is guided by the desire to ensure that our clients are provided the best possible solutions in optimal timeframe. GMI stands by its commitment to service, providing timely assistance in both pre-sales and post-sales support for our clients.

GMIPulse, our report store

We have introduced ‘GMIPulse’, which is our report store; designed to offer clients a one-stop platform for all market research and business intelligence requirements. Clients can access reports, presentations, raw data excel sheets as well as detailed company profiles. GMIPulse allows you to track relevant industries and stay informed with latest innovation, competitive and regulatory developments to help design strategic framework.

Chat with us
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies. More info X